Aytu BioScience is trading 6.73% up at $2.38 after September 22, 2026 fiscal fourth-quarter results highlighted EXXUA’s commercial momentum. - EXXUA generated $3.9 million in first-full-quarter revenue; prescriptions rose approximately 138% sequentially and shipments nearly 40%. - Revenue reached $16.1 million, while net loss narrowed to approximately break-even. - Management expects more consistent positive adjusted EBITDA during fiscal 2027; investors may also be responding to that outlook.